Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4219-4224

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Galluzzo, Sara ^a   Russo, Antonio ^b   Fulfaro, Fabio ^b   Silletta, Marianna ^a   Battistoni, Fabrizio ^a   Rocci, Laura ^a   Zobel, Bruno Beomonte ^a   Adamo, Vincenzo ^c   Dicuonzo, Giordano ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATROPINE; CAPECITABINE; CETUXIMAB; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAGNESIUM; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ACNE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; FEMALE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; LOADING DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMISTRY; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; METASTASIS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 48249132094     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0077     Document Type: Article

References (31)

1. Dai U, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001;81:51-84.
2. Romani AM, Scarpa A. Regulation of cellular magnesium. Front Biosci 2000;5:720-34.
3. Kumar BP, Shivakumar K, Kartha CC. Magnesium deficiency-related changes in lipid peroxidation and collagen metabolism in vivo in rat heart. Int J Biochem Cell Biol 1997;29:129-34.
4. Anastassopoulou J, Theophanides T. Magnesium-DNA interactions and the possible relation of magnesium to carcinogenesis. Irradiation and free radicals. Crit Rev Oncol Hematol 2002;42:79-91.
5. Rubin H. Central roles of Mg2+ and MgATP2- in the regulation of protein synthesis and cell proliferation: significance for neoplastic transformation. Adv Cancer Res 2005;93:1-58.
6. Lapidos KA, Woodhouse EC, Kohn EC, Masiero L. Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement. Angiogenesis 2001;4:21-8.
7. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother 1994;28:220-6.
8. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-7.
9. Cunningham D, HumbletY, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
10. Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 2006;94:792-7.
11. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer R J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
12. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
14. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. BrJ Cancer1977;35:1-39.
15. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
16. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004;1689:13-21.
17. Wolf Fl, Maier JA, Nasulewicz A, et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2007;458:24-32.
18. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-94.
19. Fakih MG, Wilding G, Lombardo J. Cetuximabinduced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-6.
20. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
21. Saltz LB, Meropol NJ, Loehrer PJ, Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
22. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 2005;23:1803-10.
23. Janne PA, Engelman JA. Johnson BE. et al Epidermal growth factor receptor mutations in non-smallcell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
24. Tsuchihashi Z. Khambata-Ford S. Hanna N, et al Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005;353:208-9.
25. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
26. Lièvre A. Bachet JB, BoigeV, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 2008;26:374-9.
27. Khambata-Ford S, Garrett CR, Meropol NJ, et al Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 2007;25:3230-7.
28. Scartozzi M, Bearzi I, Pierantoni C, et al Nuclear factor-kB tumor expression predicts response and survival in innotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy J Clin Oncol 2007;25:3930-5.
29. Frattini M, Saletti P Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 2007; 97:1139-45.
30. Vincenzi B, Santini D, Russo A. et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007;4:319-27
31. Vincenzi B, Santini D, Russo A, et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006;17:835-41